TD Cowen raised the firm’s price target on Krystal Biotech to $208 from $160 and keeps an Outperform rating on the shares. The firm said Vyjuvek’s strong 4Q23 performance suggests continuing patient/prescriber demand and robust market share, reaffirmingtheir confidence in the launch and 2024 Best Idea thesis.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on KRYS:
- New Sales & Marketing Risk for Krystal Biotech, Inc. – What’s the Latest?
- Krystal Biotech, Inc. (KRYS) Q4 Earnings Cheat Sheet
- Krystal Biotech to Report Fourth Quarter and Full Year 2023 Financial Results on February 26, 2024
- Krystal Biotech receives FDA Fast Track Designation for KB707
- Krystal Biotech Receives FDA Fast Track Designation for Inhaled Oncology Candidate KB707 to Treat Solid Tumors of the Lung
